Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression PipelineMarket Beat·14 hours agoTNXP0.00%
Tonix Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 13.54 MEarnings Watch·Aug 10 at 06:17 AMTNXP0.00%
Tonix Pharma CEO to speak at Canaccord Growth Conference fireside chatPUBT·Aug 5 at 06:04 AMTNXP0.00%
Tonix publishes investor deck highlighting TONMYA fibromyalgia launch and pipeline updatesPUBT·Aug 3 at 04:43 PMTNXP0.00%
Tonix plans adaptive Phase 2 trial of TNX-4800 antibody to prevent Lyme disease, targets Q1 2027 startPUBT·Aug 3 at 06:03 AMTNXP0.00%
Tonix Pharmaceuticals posts investor deck focused on TONMYA fibromyalgia launch and pipeline updatesPUBT·Jul 28 at 06:30 AMTNXP0.00%
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026Unusual Whales·Jul 27 at 06:02 AMTNXP0.00%
